Ionis's Spinraza Still Bests Novartis's Zolgensma (NYSE:NVS) | Seeking Alpha
Risdiplam trials: exciting early results in Firefish – TreatSMA
Higher-dose Spinraza SMA Trial Now Enrolls After No Safety Issues Found
Later-Onset SPINRAZA® (nusinersen) Efficacy | HCP
Biogen's Spinraza scores later-onset SMA data for stepped-up push with payers | Fierce Pharma
SMA treatment: Novartis and Biogen face lost market opportunities
Later-Onset SPINRAZA® (nusinersen) Efficacy | HCP
From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1 - Pediatric Neurology
Later-Onset SMA (Types 2 & 3)| SPINRAZA® (nusinersen)
Drug Trials Snapshots: SPINRAZA | FDA
Clinical Trials for Spinal Muscular Atrophy - Cure SMA
Later-Onset SMA (Types 2 & 3)| SPINRAZA® (nusinersen)
Early-Onset SPINRAZA® (nusinersen) Efficacy | HCP
Interim results: Infantile-onset SMA | SPINRAZA® (nusinersen) HCP
Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials | SpringerLink
Later-Onset SMA (Types 2 & 3)| SPINRAZA® (nusinersen)
Spinraza Can Restore Motor Function in Children With Late-Onset SMA, Study Finds
Drug Trials Snapshots: SPINRAZA | FDA
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study - Neuromuscular Disorders
Risdiplam trials: early results of Sunfish – TreatSMA
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy | NEJM
Spinraza Clinical Trial Update: Boy With Type 1 SMA Progressing Well - SMA News Today
Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden | SpringerLink
Therapeutic approaches for spinal muscular atrophy (SMA) | Gene Therapy
Later-Onset SMA (Types 2 & 3)| SPINRAZA® (nusinersen)
Drug Trials Snapshots: SPINRAZA | FDA
